Medicamen Biotech Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

| Updated on May 30, 2019 Published on May 30, 2019

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015, we wish to inform you that the Board of Directors of our Company in its meeting held today i.e. on May 30, 2019 had among other matters, considered and approved the following:-

I. Appointment of Dr Ravi Kumar Bansal (DIN:08462513) an Additional Director (Independent) Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held on 30th May, 2019 has decided to appoint Dr. Ravi Kumar Bansal as an Additional Director (Independent) of the Company for a period of 5 years with immediate effect subject to the approval of shareholders in the ensuing General Meeting.

Relevant details as required under Regulation 30 of the Listing Regulations read with SEBI circular No CIR/CFDCMD/4/2015, dated September 9, 2015 are enclosed as Annexure A.

This is for your information and record.

Pdf Link: Medicamen Biotech Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

Source : BSE - www.bseindia.com

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 30, 2019
This article is closed for comments.
Please Email the Editor